|
| Status |
Public on Nov 02, 2017 |
| Title |
SMARCB1+ day7 2 |
| Sample type |
RNA |
| |
|
| Source name |
I2A SMARCB1-reexpressed cell line
|
| Organism |
Homo sapiens |
| Characteristics |
genotype/variation: I2A SMARCB1-reexpressed
tissue: rhabdoid tumor cell line
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNAs were collected from samples using the miRNeasy kit (Qiagen) according to the manufacturer's instructions
|
| Label |
biotin
|
| Label protocol |
According to the standard Affymetrix protocol
|
| |
|
| Hybridization protocol |
Hybridization performed by Institut Curie Affymetrix Microarray Core Facility according to the manufacturer's instructions
|
| Scan protocol |
Scanning were performed by Institut Curie Affymetrix Microarray Core Facility according to the manufacturer's instructions
|
| Description |
MM27_ARN0011_s2h1_C07_hGene2.1
|
| Data processing |
Arrays were normalized by the GCRMA procedure using Brainarray annotations (V.16.0.0, ENTREZG)
|
| |
|
| Submission date |
Apr 27, 2017 |
| Last update date |
Jan 23, 2018 |
| Contact name |
Wilfrid Richer |
| E-mail(s) |
[email protected]
|
| Organization name |
Institut Curie
|
| Street address |
26 rue d'Ulm
|
| City |
Paris |
| ZIP/Postal code |
75005 |
| Country |
France |
| |
|
| Platform ID |
GPL19264 |
| Series (1) |
| GSE98277 |
High-Throughput Drug Screening identifies Pazopanib and Clofilium tosylate as effective treatments for malignant rhabdoid tumors |
|
